>>>   Click for Diagenode’s approach to COVID-19


With RNAi across the hemophilia
October 23, 2015

RNA interference (RNAi) may be used as a therapeutic for the bleeding disorder hemophilia. Specifically, artificially-generated, epigenetically-activated RNA molecules such as microRNAs can be used to inhibit gene expression through post-translational gene silencing. Researchers from France and the USA recently treated hemophiliac mice and macaques with a successful RNAi compound (ALN-AT3), which supresses the production of the anti-clotting substance antithrombin. Currently this therapeutic is being investigated in phase 1 clinical trials in individuals with hemophilia A or B.

Source: http://www.newsletter-epigenetik.de/

Read more


  • DNA methylation workshop: Become an expert at RRBS
    Oct 1-Oct 31, 2021
  • Dutch Chromatin Meeting
    Radboud UMC, Geert Grooteplein 15, 6525 EZ Nijmegen, The Netherlands, Experience center, route 292 to 307
    Nov 12, 2021



The European Regional Development Fund and Wallonia are investing in your future.

Extension of industrial buildings and new laboratories.


       Site map   |   Contact us   |   Conditions of sales   |   Conditions of purchase   |   Privacy policy   |   Diagenode Diagnostics